Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of TDM-optimized versus standard teicoplanin dosing
NL-OMON59377Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in sepsis comparing TDM-guided teicoplanin dosing with Standard dosing / standard of care (2 arms). Primary endpoint: Primary: target attainment at day 5. Started Aug 2023; status: completed.
02
Drugs
teicoplanin
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON59377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59377.